Marc Robillard

Tagworks Pharmaceuticals BV is a Dutch precision therapy company that develops a new standard of care for patients suffering from severe diseases, including cancer. Tagworks Pharmaceuticals is based in and the Netherlands. The company leverages its technology platform, which is protected by a broad patent estate, to pioneer the click-to-release approach. Tagworks is developing a pipeline of click-cleavable therapies, including its lead program, TGW101, an antibody-drug conjugate targeting TAG72. The company's technology enables on-target activation of ADCs and immunomodulators, as well as off-target deactivation of radioimmunotherapies to enhance their therapeutic index. The company was founded in 2011 by Raffaella Rossin, Zach Taylor, Marc Robillard, and Marc Robillard has been the CEO since 2011.